Olanzapine-induced neuroleptic malignant syndrome with mental retardation.
H C
HC
Margolese
G
G
Chouinard
D000328:Adult; D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001569:Benzodiazepines; D015897:Comorbidity; D006801:Humans; D008607:Intellectual Disability / Q000453:epidemiology*; D008297:Male; D001523:Mental Disorders / Q000188:drug therapy / Q000453:epidemiology; D009459:Neuroleptic Malignant Syndrome / Q000453:epidemiology / Q000209:etiology*; D000077152:Olanzapine; D010890:Pirenzepine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use
D014150:Antipsychotic Agents; D001569:Benzodiazepines; D010890:Pirenzepine; D000077152:Olanzapine